BEVERLY, Mass., June 9, 2011 /PRNewswire/ -- Enzymatics, Inc. announced today that the company, whose revenues have doubled every year since 2007, is forecasting triple the revenue in 2011 over 2010 figures. It is also expanding its corporate offices and manufacturing facility in Beverly, Massachusetts. The move is one of several significant milestones for the five year-old, privately held firm that supplies biological reagents as well as bio-processing consulting services to the international scientific and healthcare markets. It also demonstrates that Massachusetts is no longer just a biotech R&D nursery and is quickly becoming an international center for biotech manufacturing.
Enzymatics’ proprietary manufacturing process produces commercial quantities of enzymes measurably superior in purity and consistency to those created in small batches for the research field but at a much lower cost. The timing couldn’t be better as national and international bioscience and pharmaceutical companies rush to create genomic diagnostics and bio-ceutical drug therapies for mass-market distribution. Reagents are critical components of these products and in Enzymatics, their manufacturers have found an ideal partner supplier that can scale up to meet large production levels while exceeding purity standards and keeping costs down.
“Our growth and expansion are a great confirmation that we had the right vision at exactly the right time,” states Enzymatics Co-Founder and President Chris Benoit. “It’s been an incredible ride that’s about to get even more exciting as we expand our presence in larger, international markets.” The company is currently establishing its first full-service overseas office in Europe. Enzymatics now supports a full time staff of more than 50 and is actively looking to fill an additional 15 positions.
When asked to share his own perspective on the company’s progress, Co-Founder and CEO Stephen Picone replied, “You can sense the future here...We’re perfecting new manufacturing technologies built on our core competencies. And the key collaborations we’re setting up will lay the groundwork for the development of novel enzymes. Both of these initiatives will add a great deal of value to our customer’s businesses.”
ABOUT ENZYMATICS: Enzymatics is a leading biotechnology and biosciences manufacturing company that delivers ISO 13485-compliant enzymes of unrivaled purity, consistency, and value to the healthcare and bioscience industries. For more information, please visit www.enzymatics.com.
Lisa Lazarczyk
781-646-0667 or lisa@lazpr.com
SOURCE Enzymatics, Inc.
